A new report from the RAND Corporation released in January 2026 provides a sobering look at the landscape of psychedelic use in the United States. As we move further into this “psychedelic renaissance,” it is critical to separate clinical interest from the forensic and toxicological realities we face in the field.
DRE Classifications vs. Pharmacological Reality
While the term “psychedelic” is often used as a catch-all in the media, Drug Recognition Experts (DREs) and forensic toxicologists categorize these substances based on their physiological effects and impairment patterns. The top five substances identified in the RAND research illustrate why a one-size-fits-all approach doesn’t work:
- Psilocybin / Psilocin
- DRE Classification: Hallucinogen
- Mechanism: Serotonin (5-HT2A) Agonist
- LSD
- DRE Classification: Hallucinogen
- Mechanism: Serotonin/Dopamine Agonist
- Amanita muscaria
- DRE Classification: Hallucinogen
- Mechanism: GABAA Agonist (Muscimol/Ibotenic Acid)
- MDMA
- DRE Classification: Stimulant / Hallucinogen
- Mechanism: Serotonin, Norepinephrine, and Dopamine Reuptake Inhibitor
- Ketamine
- DRE Classification: Dissociative Anesthetic
- Mechanism: NMDA Receptor Antagonist
For law enforcement and clinicians, these distinctions are vital. For instance, while psilocybin primarily affects serotonin, Amanita muscaria acts on GABA receptors, leading to a much higher risk of central nervous system depression, seizures, and respiratory failure.
The Forensic Toxicology Challenge
In the crime lab, these substances remain relatively rare in routine casework. This is not necessarily because they aren’t being used, the RAND report suggests 10 million U.S. adults microdosed in 2025 alone, but because they present significant analytical hurdles:
- Detection Windows: Substances like LSD and psilocin have very short half-lives and low concentrations in biological matrices, making them difficult to detect without targeted, high-sensitivity LC-MS/MS methods.
- Impairment Patterns: Unlike stimulants or depressants, pure hallucinogens rarely correlate with “typical” drug-facilitated crimes or impaired driving cases, as the user is often too incapacitated to engage in complex tasks.
- The “Ecstasy” Variable: MDMA is frequently found in “Ecstasy” or “Molly” pills, but forensic analysis often reveals a cocktail of synthetic cathinones (bath salts), methamphetamine, and even other hallucinogens like 2C-B or DMT.
Note: We are seeing an increase in these substances in postmortem toxicology, where hallucinations may lead to secondary “accidental” fatalities due to dangerous behaviors.
Clinical Interest vs. Public Risk
The FDA recently scrutinized stage 3 clinical trials for MDMA-assisted therapy for PTSD. While the therapeutic potential is significant, the FDA issued a Complete Response Letter in late 2024 (with ongoing discussions into 2025) citing concerns over trial design and data validity rather than the drug’s efficacy itself.
However, the “health halo” surrounding these trials has led to a surge in unregulated use. The RAND report highlights that 69% of psilocybin users in 2025 engaged in microdosing. The danger lies in the lack of regulation:
- Smoke Shop Products: Many products claiming to be “legal” or “natural” have been found to contain undisclosed synthetic tryptamines or even multiple different psychedelics in one dose.
- Amanita Toxicity: Unlike “magic mushrooms,” Amanita muscaria is legally available in many states but carries severe risks, including hypoxia, acute respiratory failure, and altered mental status.
Moving Forward
As we monitor the 2026 data, the trend is clear: use is moving from the fringe to the mainstream. Until these substances move from “unregulated and illicit” to “government-approved treatments,” the risks of contamination, misidentification, and acute toxicity remain high.
References
- U.S. Psychedelic Use and Microdosing in 2025 – RAND
- https://www.fda.gov/food/hfp-constituent-updates/fda-alerts-industry-and-consumers-about-use-amanita-muscaria-or-its-constituents-food
- https://www.cdc.gov/mmwr/volumes/68/wr/mm6821a4.htm
- https://www.science.org/doi/epdf/10.1126/science.ads4470
Disclaimer: The opinions and information in the post do not necessarily reflect those of my employer or associated/partner organizations.
